RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 45 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 45

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Inner Mongolia Medical University内蒙古医科大学附属医院HohhotHospital page
  2. Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
  3. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  4. Study siteBeijing Chest Hospital首都医科大学附属北京胸科医院BeijingHospital page
  5. Study siteCentral Hospital Affiliated to Shandong First Medical University山东第一医科大学附属中心医院(济南市中心医院)JinanHospital page
  6. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  7. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  8. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  9. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  10. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  11. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  12. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  13. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  14. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  15. Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
  16. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  17. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  18. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  19. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  20. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  21. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  22. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  23. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  24. Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
  25. Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
  26. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  27. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  28. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  29. Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
  30. Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
  31. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page
  32. Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
  33. Study siteShanghai Tenth People's Hospital上海市第十人民医院ShanghaiHospital page
  34. Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
  35. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  36. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  37. Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page
  38. Study siteTianjin Chest Hospital天津市胸科医院TianjinHospital page
  39. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  40. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  41. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  42. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  43. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  44. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  45. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07185997, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 1

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (1 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07185997, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Key Eligibility Criteria:

  • Histologically or cytologically documented, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy.
  • Documented results of the presence of an Epidermal Growth Factor Receptor (EGFR) PACC mutation in tumor tissue or blood from local testing.
  • No prior systemic anticancer therapy regimens received for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) including prior treatment with any Epidermal Growth Factor Receptor (EGFR)-targeting agents (e.g., previous (EGFR) TKIs, monoclonal antibodies, or bispecific antibodies).
  • Patients who have received prior neo-adjuvant and/or adjuvant chemotherapy, immunotherapy, or chemo radiotherapy for non-metastatic disease must have experienced a treatment free interval of at least 12 months.
  • Patients with asymptomatic CNS metastases are eligible.
  • List of eligible PACC mutations:

E709X, E709A, E709H, E709V, E709K E709_T710delinsD, E709_T710delinsA, E709_T710delinsG, L718M, L718P, L718Q, L718V, G719X, G719A, G719C, G719D, G719S, G724S, E736K, I740_K745dup, I740_K745dupIPVAIK, I744_K745insKIPVAI, L747P, L747S, K757M, K757R, V765L, S768I, S768_V769delinsIL, S768_V769delinsIM, S768_V769delinsPL, V769L, V769M, N771G, H773_V774delinsLM, V774M, R776C, R776H, G779F, L792H, G796S, T854A, T854S, T854I, A647T, R675W, S768C, A755D, A750_I759delinsPN, T751_I759delinsN

Quoted from ClinicalTrials.gov, NCT07185997, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07185997, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07185997